SELLAS Life Sciences Group Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for SELLAS Life Sciences Group, Inc. (SLS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-30.88-37.34-41.30-20.70-16.76-19.29-27.67
Depreciation & Amortization0.000.500.000.000.000.000.00
Deferred Income Tax0.000.000.00-0.24-0.02-0.10-1.32
Stock Based Compensation1.562.091.731.010.580.000.00
Change in Working Capital-6.653.355.64-7.625.87-1.11-10.01
Change in Accounts Payable-2.142.301.21-2.51-0.840.000.00
Change in Other Working Capital0.560.504.43-4.161.110.000.00
Other Operating Activities0.560.500.13-4.16-0.112.864.42
Net Cash from Operating Activities-35.40-31.41-23.81-26.02-10.42-17.64-30.42
Investing Activities
Capital Expenditures0.00-5.50-4.500.000.000.000.00
Acquisitions0.00-5.50-4.500.000.000.000.00
Sales/Maturities of Investments0.00-5.50-4.500.000.000.000.00
Net Cash from Investing Activities0.00-5.50-4.500.000.000.000.00
Financing Activities
Debt Repayment0.000.000.000.000.000.00-7.60
Common Stock Issued46.1622.2324.089.0138.4415.9731.21
Common Stock Repurchased-0.06-0.030.000.000.000.000.00
Dividends Paid0.000.000.000.000.000.00-0.49
Other Financing Activities-0.06-0.030.000.000.313.600.00
Net Cash from Financing Activities46.7622.3224.0812.0738.4419.5723.12
Summary
Net Change in Cash11.36-14.60-4.23-13.9528.031.93-7.30
Cash at Beginning of Period2.6317.2321.4635.407.385.4512.75
Cash at End of Period13.992.6317.2321.4635.407.385.45
Free Cash Flow-35.40-36.91-23.81-26.02-10.42-17.64-30.42
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.000.32